Stockscreener 앱 받기
0.61
4.17%
-0.037
전일 마감가:
$0.647
열려 있는:
$0.645
하루 거래량:
96,440
Relative Volume:
0.60
시가총액:
$39.69M
수익:
$76.19M
순이익/손실:
$-1.61M
주가수익비율:
61.00
EPS:
0.01
순현금흐름:
$28.98M
1주 성능:
-12.68%
1개월 성능:
+6.53%
6개월 성능:
-52.67%
1년 성능:
-61.96%
1일 변동 폭
$0.61
$0.668
1주일 범위
$0.61
$0.7169
52주 변동 폭
$0.5052
$1.72
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
SPRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
0.62 | 39.69M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.32 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.68 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.79 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.40 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.46 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times
Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune
Spero Therapeutics Confirms Q1 Earnings Date: Latest Updates on Rare Disease and MDR Programs Coming May 13 - Stock Titan
Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Appoints Esther Rajavelu as CEO - citybiz
New Leadership Announcement for Spero Therapeutics (SPRO) | SPRO Stock News - GuruFocus
Spero Therapeutics appoints new CEO and board nominee - Investing.com
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer - GlobeNewswire
Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer - marketscreener.com
Spero Therapeutics Promotes CFO to CEO Role as Critical Phase 3 Trial Results Approach - Stock Titan
Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire
Spero Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc. - MarketScreener
Virtu Financial LLC Makes New $47,000 Investment in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate - Yahoo Finance
Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast - Investing.com India
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: - GuruFocus
Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast By Investing.com - Investing.com South Africa
Spero Therapeutics earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Spero Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq
Spero Q4 Earnings: $68.6M Loss, Pipeline Setbacks, and New Interim CEO Named - Stock Titan
A Glimpse of Spero Therapeutics's Earnings Potential - Benzinga
Spero Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Spero Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
Spero Therapeutics Q4 Earnings: Rare Disease Pipeline and Financial Results Coming March 27 - StockTitan
Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025 - Yahoo Finance
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - The AM Reporter
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges - Investing.com Australia
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges By Investing.com - Investing.com South Africa
Spero Therapeutics (SPRO) Projected to Post Earnings on Wednesday - The AM Reporter
Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN
Spero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Spero Therapeutics faces Nasdaq delisting over share price - Investing.com India
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire
UPDATESpero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Marjorie Taylor Greene Is Betting Big on Palantir Stock. Should You? - The Globe and Mail
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.37%
0.04%
자본화:
|
볼륨(24시간):